Veru (VERU) Notes Receivable : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 1990. Start your Free Trial

What is Veru Notes Receivable?

Veru's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.

Veru Notes Receivable Historical Data

The historical data trend for Veru's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Notes Receivable Chart

Veru Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Notes Receivable

Get a 7-Day Free Trial

5.00

Veru Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Veru Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Veru Notes Receivable Related Terms

Thank you for viewing the detailed overview of Veru's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Veru Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

FMW:Germany FMW:Germany

Address

2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127

Website

https://www.verupharma.com

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Executives

Michael L Rankowitz	director	2500 LAKE COOK ROAD, RIVERWOODS IL 60015
K Gary Barnette	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Mitchell Shuster Steiner	director, 10 percent owner, officer: President and CEO	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
Harry Fisch	director, 10 percent owner	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Mario Eisenberger	director	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Lucy Lu	director	THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Grace Hyun	director	48 NW 25TH STREET, SUITE 102, MIAMI FL 33127
Michele Greco	officer: VP and CFO	515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654
Jesus Socorro	director	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Todd Charles T Jr	officer: CEO of FHC Division	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Robert Getzenberg	officer: Chief Scientific Officer	4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elgar Peerschke	director	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Daniel Haines	officer: CFO and COO	515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
David R Bethune	director	THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610
O B Parrish	director, officer: Chairman/Chief Exec. Officer